See Exam. Amendment (3/18/04)



**In the Claims:**

The following listing of claims will replace any/all prior versions, and listings, of claims in the application:

Claim 1 (Currently Amended): A method of treating or suppressing the symptoms of at least one disorder selected from addictive disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction, and nicotine addiction, said method comprising the step of administering to a patient in need of treatment a therapeutically effective, nontoxic amount of an active agent selected from the group consisting of a phenylazacycloalkane, a cabergoline, an aromatic bicyclic amine and a heterocyclic amine of the formula:

Sub claim 1 of 3/18/04




or a pharmaceutically acceptable salt thereof, wherein:

$R^1$, $R^2$, and $R^3$ are each independently hydrogen, $C_{1-6}$ alkyl, $C_{3-5}$ alkenyl, $C_{3-5}$ alkynyl, $C_{3-7}$ cycloalkyl, $C_{4-10}$ cycloalkyl- or phenyl- substituted $C_{1-6}$ alkyl, or $R^1$ and $R^2$ are joined to form a $C_{3-7}$ cyclic amine which can contain additional heteroatoms and/or unsaturation;

n is 0 or 1;

X is hydrogen, $C_{1-6}$ alkyl, halogen, hydroxy, alkoxy, cyano, carboxamide, carboxyl, or carboalkoxyl;

A is CH, $CH_2$, CH-halogen, $CHCH_3$, C=O, C=S, $C\text{-}SCH_3$, C=NH, $C\text{-}NH_2$, $C\text{-}NHCH_3$, $C\text{-}NHCOOCH_3$, C-NHCN, $SO_2$, or N;

B is $CH_2$, CH, CH-halogen, C=O, N, NH, $N\text{-}CH_3$, or O;

D is CH, $CH_2$, CH-halogen, C=O, O, N, NH, or $N\text{-}CH_3$; ~~and a phenylazacycloalkane, a cabergoline, an aromatic amine~~

and pharmaceutically acceptable derivatives or salts of any said active agent.

Claim 2 (canceled)

2

Claim ~~3~~ (Currently Amended): The method of claim 1 ~~2~~, wherein:

D is N or NH, and n is 0~~, and $R^1$, $R^2$, $R^3$, X, A, and B are as defined in claim 2~~; or

A is CH, $CH_2$, $CHCH_3$, C=O, C=S, C-$SCH_3$, C=NH, C-$NH_2$, C-$NHCH_3$, C-$NHCOOCH_3$, or C-NHCN~~, and $R^1$, $R^2$, $R^3$, n, X, B, and D are as defined in claim 2; or~~

~~A is CH or C=O, and $R^1$, $R^2$, $R^3$, n, X, B, and D are as defined in claim 2~~ .

3

Claim ~~4~~ (Currently Amended): The method of claim 1 ~~2~~ wherein the active agent is selected from the group consisting of:

~~(5R)-5-(methylamino)-5,6-dihydro-4H-imidao[4,5,1-ij]quinolin-(2H)-one~~ (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one;

(5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione;

(5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione maleate; and

(5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione 2-butenedioanate.

Claims 5-12 (Canceled).

4

Claim ~~13~~ (Original): The method of claim 1 wherein the active agent is used to treat or enhance the treatment of tobacco and/or nicotine addiction.

5

Claim ~~14~~ (Original): The method of claim 1 wherein the active agent is used to reduce the craving for tobacco and/or nicotine containing products.

6

Claim ~~15~~ (Original): The method of claim 1 wherein the active agent is used to reduce the smoking and/or chewing of tobacco or nicotine-containing products.

Claim 16 (Original): The method of claim 1 wherein the active agent is administered to the patient three times a day.

Claim 17 (Original): The method of claim 1 wherein the active agent is ~~selected from the group consisting of a heterocyclic amine, a phenylazacycloalkane, and a cabergoline~~ administered in a dose of about 0.01 mg/day to about 10.0 mg/day.

see paper 3/18/04 VA

Claim 18 (Original): The method of claim 17 wherein the active agent is ~~selected from the group consisting of a heterocyclic amine, a phenylazacycloalkane, a cabergoline, and a cabergoline-type derivative~~ administered in a dose of about 0.125 mg/day to about 6 mg/day.

see paper 3/18/04 VA

Claim 19 (Original): The method of claim 18 wherein the active agent is administered in an amount from about 0.375 mg/day to about 5 mg/day.

Claim 20 (Original): The method of claim 19 wherein the active agent is administered in an amount from about 0.75 mg/day to about 4.5 mg/day.

Claim 21 (Original): The method of claim 17 wherein an initial dose of active agent of about 0.125 mg/day administered to the patient three times a day is titrated to higher levels every five to seven days until therapeutic effect is achieved.

Claims **22-25** (Canceled).